瑞典隆德大学Oskar Hansson、Shorena Janelidze等研究人员合作揭示,血浆磷酸化tau181(P-tau181)蛋白与阿尔茨海默氏症(AD)的关联性。相关论文于2020年3月2日在线发表于《自然—医学》。
Title: Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
Author: Shorena Janelidze, Niklas Mattsson, Sebastian Palmqvist, Ruben Smith, Thomas G. Beach, Geidy E. Serrano, Xiyun Chai, Nicholas K. Proctor, Udo Eichenlaub, Henrik Zetterberg, Kaj Blennow, Eric M. Reiman, Erik Stomrud, Jeffrey L. Dage, Oskar Hansson
Issue&Volume: 2020-03-02
Abstract: Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer’s disease (AD), but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P-tau181 in three cohorts, with a total of 589 individuals, including cognitively unimpaired participants and patients with mild cognitive impairment (MCI), AD dementia and non-AD neurodegenerative diseases. Plasma P-tau181 was increased in preclinical AD and further increased at the MCI and dementia stages. It correlated with CSF P-tau181 and predicted positive Tau positron emission tomography (PET) scans (area under the curve (AUC)=0.87–0.91 for different brain regions). Plasma P-tau181 differentiated AD dementia from non-AD neurodegenerative diseases with an accuracy similar to that of Tau PET and CSF P-tau181 (AUC=0.94–0.98), and detected AD neuropathology in an autopsy-confirmed cohort. High plasma P-tau181 was associated with subsequent development of AD dementia in cognitively unimpaired and MCI subjects. In conclusion, plasma P-tau181 is a noninvasive diagnostic and prognostic biomarker of AD, which may be useful in clinical practice and trials.
DOI: 10.1038/s41591-020-0755-1
Source: https://www.nature.com/articles/s41591-020-0755-1
Nature Medicine:《自然—医学》,创刊于1995年。隶属于施普林格·自然出版集团,最新IF:30.641
官方网址:https://www.nature.com/nm/
投稿链接:https://mts-nmed.nature.com/cgi-bin/main.plex